MYELODYSPLASTIC SYNDROMES: Genetics of MDS
With the use of advanced genomics this article provides a comprehensive registry of driver mutations recurrently found in MDS patients and correlates these with disease phenotype and prognosis.
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator
MDS Factsheet for GPs General Practicioners
Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.
This is an external link to the home of the British Society for Haematology (BSH).